Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster ...

ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors; Two ADC ...

Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the ...

Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19 ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation ...

Programmers learning Rust struggle to understand own\x02ership types, Rust’s core mechanism for ensuring memory safety ...

Five new artists-in-residence have kicked off their yearlong projects at Mount Auburn Cemetery, bringing an eclectic mix of ...

Museum Night 2024 takes place on Saturday, May 18, 2024 across France. In Paris, we'll be taking advantage of a host of events, notably at the Palais de Tokyo, which has some great surprises in store ...

In April, the American Red Cross asks people to keep patients top of mind by making an appointment to give blood or platelets ...

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...

New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] ...

Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality ...